ProMIS Neurosciences, a biotech company focused on antibody therapeutics for neurodegenerative diseases, will announce its Q3 2026 financial results on November 12, 2026. The company will also provide updates on its lead Alzheimer's drug candidate, PMN310, during a conference call and webcast at 4:30 p.m. ET. Investors can access a replay of the webcast on ProMIS' website. This update is important as PMN310 targets toxic amyloid-beta oligomers, potentially advancing Alzheimer's treatment.
ProMIS Neurosciences' upcoming Q3 2026 financial results provide context for health-sector market activity. For readers following health stocks on Pluang as of Nov 03, 2026 19:02 WIB, 74 of 150 US health-sector stocks rose while 69 fell. Among notable movers, Nuvation Bio Inc. gained 4.79% to USD 4.81 with a typical hold time of 18 days, contrasting with Travere Therapeutics Inc. which dropped 3.98% to USD 47.30 and a hold time of 19 days.
Anavex Life Sciences appointed Terrie Kellmeyer, Ph.D., as President and CEO, also joining the Board. Kellmeyer, with over 30 years in biopharma, has led the company through key clinical milestones including FDA clearance for Fragile X syndrome trial...
Cardiff Oncology, a clinical-stage biotech company focusing on cancer therapies via PLK1 inhibition, announced it will present at the UBS Global Biopharma Conference on November 16-17, 2026. The company's CEO, Mani Mohindru, will deliver a fireside c...
Seyond Inc is enhancing its smart city solutions by integrating advanced LiDAR 3D sensing with AI-powered analytics and collaborations with Dell Technologies, NVIDIA, and AMSYS. This expansion supports improved safety, transportation, and infrastruct...
Stella-Jones Inc. announced a teleconference on November 4, 2026, at 10:00 AM EST to discuss its third-quarter 2026 financial results. The event is open to investors, analysts, and interested parties, with live streaming and phone access provided. A ...
Stella-Jones Inc. announced a conference call for November 4, 2026, at 10:00 AM EST to discuss its third quarter 2026 financial results. The call is open to investors, analysts, and interested parties and will be webcast live with a recording availab...
